Vaccine documents, young leaders and market turmoil: Endpoints' 10 biggest stories of 2022
It’s been a volatile year in the world of biopharma. Market declines reset M&A valuations, and may be beginning to tempt bigger buyers back into dealmaking. Russia’s war in Ukraine disrupted drug sales and clinical trials. A new generation of young biotech leaders emerged in the Endpoints 20(+1) Under 40. And as capital runs dry in a tough environment for raising new funds, companies big and small are taking a look at their headcounts and operations for ways to make it through lean times.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.